OA19279A - Treatment for Parkinson's disease. - Google Patents
Treatment for Parkinson's disease. Download PDFInfo
- Publication number
- OA19279A OA19279A OA1201800475 OA19279A OA 19279 A OA19279 A OA 19279A OA 1201800475 OA1201800475 OA 1201800475 OA 19279 A OA19279 A OA 19279A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- formula
- alkyl
- hydrogen
- halogen
- Prior art date
Links
- 206010061536 Parkinson's disease Diseases 0.000 title claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 30
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims abstract description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 26
- 239000001257 hydrogen Substances 0.000 claims abstract description 26
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 19
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 18
- 150000002367 halogens Chemical class 0.000 claims abstract description 18
- 125000004432 carbon atoms Chemical group C* 0.000 claims abstract description 13
- 125000003118 aryl group Chemical group 0.000 claims abstract description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 18
- 102000031061 Tyrosine 3-monooxygenases Human genes 0.000 description 17
- 108091000118 Tyrosine 3-monooxygenases Proteins 0.000 description 17
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 14
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 14
- 229960001346 nilotinib Drugs 0.000 description 14
- 210000004556 Brain Anatomy 0.000 description 13
- 210000002569 neurons Anatomy 0.000 description 13
- PLRACCBDVIHHLZ-UHFFFAOYSA-N MPTP Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 102000017094 parkin protein Human genes 0.000 description 11
- 108091004085 parkin protein Proteins 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 101700060519 PTPN2 Proteins 0.000 description 9
- 102000003802 alpha-Synuclein Human genes 0.000 description 9
- 108090000185 alpha-Synuclein Proteins 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 8
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 7
- 210000004027 cells Anatomy 0.000 description 7
- 229960002448 dasatinib Drugs 0.000 description 7
- 230000003291 dopaminomimetic Effects 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 5
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 5
- 230000036451 QT interval Effects 0.000 description 5
- 230000035887 QTcF INTERVALS Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- -1 hydrocarbon chain radical Chemical class 0.000 description 5
- 229960002411 imatinib Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 4
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- PHXJVRSECIGDHY-UHFFFAOYSA-N Ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 4
- 238000000543 QT interval Methods 0.000 description 4
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 4
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000271 cardiovascular Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 230000000275 pharmacokinetic Effects 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 229960001131 ponatinib Drugs 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 206010053643 Neurodegenerative disease Diseases 0.000 description 3
- 229940069905 Tasigna Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000000865 phosphorylative Effects 0.000 description 3
- 230000003389 potentiating Effects 0.000 description 3
- 230000002633 protecting Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 108009000409 Autophagy Proteins 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037250 Clearance Effects 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 2
- 231100000618 Neurotoxin Toxicity 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N Pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 230000036028 QTc interval Effects 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N Suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006877 autophagy Effects 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 2
- 230000035512 clearance Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-Diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 102100000269 AIMP2 Human genes 0.000 description 1
- 101700078290 AIMP2 Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Azelaic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 230000035592 Brain Concentration Effects 0.000 description 1
- 230000036102 Brain to plasma ratio Effects 0.000 description 1
- 230000037187 Brain/plasma Effects 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- YBBJTKRMHFSVRD-UHFFFAOYSA-N ClC1=C(C(=O)NNC(=O)C=2C=CC(=C(C=2)C#CC=2C=CC(=NC=2)NC(=O)C2CCCCC2)C)C(=CC=C1)C Chemical compound ClC1=C(C(=O)NNC(=O)C=2C=CC(=C(C=2)C#CC=2C=CC(=NC=2)NC(=O)C2CCCCC2)C)C(=CC=C1)C YBBJTKRMHFSVRD-UHFFFAOYSA-N 0.000 description 1
- HCCGKJRBNMBRSK-UHFFFAOYSA-M ClC1=C(C(=O)NNC(=O)C=2C=CC(=C(C=2)C#CC=2C=CC(=NC=2)[NH-])C)C(=CC=C1)C Chemical compound ClC1=C(C(=O)NNC(=O)C=2C=CC(=C(C=2)C#CC=2C=CC(=NC=2)[NH-])C)C(=CC=C1)C HCCGKJRBNMBRSK-UHFFFAOYSA-M 0.000 description 1
- 230000037242 Cmax Effects 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102100007414 FBP1 Human genes 0.000 description 1
- 101700031507 FBP1 Proteins 0.000 description 1
- 101700074180 FBP2 Proteins 0.000 description 1
- 229940080856 Gleevec Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229940049235 Iclusig Drugs 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 210000004731 Jugular Veins Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 1
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 description 1
- 210000004558 Lewy Bodies Anatomy 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100001553 PINK1 Human genes 0.000 description 1
- 101700023759 PINK1 Proteins 0.000 description 1
- 230000037164 Plasma conc Effects 0.000 description 1
- 208000002151 Pleural Effusion Diseases 0.000 description 1
- 206010035601 Pleural haemorrhage Diseases 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229940068988 Potassium Aspartate Drugs 0.000 description 1
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 description 1
- 102000007659 Protein Deglycase DJ-1 Human genes 0.000 description 1
- 102000004278 Receptor protein-tyrosine kinases Human genes 0.000 description 1
- 108090000873 Receptor protein-tyrosine kinases Proteins 0.000 description 1
- 210000003523 Substantia Nigra Anatomy 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 108020003835 TX1 Proteins 0.000 description 1
- 229960000351 Terfenadine Drugs 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 101710018339 YIP3 Proteins 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 230000001120 cytoprotect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 125000004431 deuterium atoms Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000002055 immunohistochemical Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- TXXVQZSTAVIHFD-DKWTVANSSA-M potassium;(2S)-2-aminobutanedioate;hydron Chemical compound [K+].[O-]C(=O)[C@@H](N)CC(O)=O TXXVQZSTAVIHFD-DKWTVANSSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000036278 prepulse Effects 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 230000000946 synaptic Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is –NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1- 3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
Description
RELATED APPLICATIONS
This application daims the benefit of Indian Patent Application no. IN 201621019087 filed on June 02, 2016 and IN 201621019185 filed on June 02, 2016; which is hereby incorporated by reference . ,
FIELD OF THE INVENTION
The invention relates to a method of treating or preventing Parkinson’s disease in a subject comprising administering a compound of Formula I
Formula I wherein, Ri is -NHC(O) C3.6 cycloalkyl and R2 is hydrogen;
or Rt and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and Ci.6 alkyl;
R3 and R4 are independently selected from group comprising hydrogen, halogen, Ον3 alkyl, OC^ alkyl, NO2, SC^ alkyl, ΟΊ.3 haloalkyl, OC^ haloalkyl, and SC^ haloalkyl; or a pharmaceutically acceptable sait thereof.
BACKGROUND OF THE INVENTION c-Abl is a non-receptor protein tyrosine kinase that is implicated in various cellular processes which include régulation of cell survival, growth and motility. c-Abl kinase inhibitors such as imatinib (Gleevec®), nilotinib (Tasigna®), dasatinib (Sprycel®) and ponatinib (Iclusig® ) hâve been developed and marketed for clinicai use in the treatment of chronic myeloid ieukemia.
Recent studies hâve demonstrated that c-Abl plays an important rôle in oxidative stressinduced neuronal cell death (Wu et al., Cell Death Differ., 2016; 23:542-552). It has been reported that c-Abl is involved in Parkinson’s disease (Gonfloni et al., Int. J. Cell Biol., 2012; 2012:1-7). Also, c-Abl is known to be activated by dopaminergic stress and by dopaminergic neurotoxins viz. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, converted enzymatically in vivo to its active form MPP+) causes tyrosine phosphorylation of parkin leading to loss of parkin’s E3 ligase activity. This results in the accumulation of various substrates of parkin and ultimately to death of dopaminergic neurons (Ko et al., PNAS, 2010; 107:16691-16696).
Parkinson disease (PD) is a common neurodegenerative disease characterized by protein accumulation in intracellular inclusions designated as Lewy bodies and Lewy neuritis and subséquent loss of dopaminergic neurons. Rare familial mutations hâve provided insight into this chronic, progressive neurodegenerative disease like mutation in α-synuclein and LRRK2 cause autosomal-dominant PD, whereas mutations in DJ-1, PINK1 and parkin results in autosomal-recessive PD. Parkin is an E3 ubiquitin ligase, and familial mutations are thought to impair E3 ligase activity of parkin (Ko et al., PNAS, 2010; 107:16691-16696).
c-Abl has been shown to regulate the dégradation of two proteins implicated in the pathogenesis of PD viz. parkin and α-synuclein (Mahul-Mellier et al., Hum. Mol. Genet., 2014; 23:2858-2879). c-Abl phosphorylâtes parkin on tyrosine 143. This phosphorylation inhibits parkin’s E3 ubiquitin ligase activity, leading to accumulation of AIMP2 and FBP1 (parkin substrates) and loss of parkin’s cytoprotective function resulting in cell death (Ko et al., PNAS, 2010; 107:16691-16696; Imam étal., J. Neurosci., 2011; 31:157-163). Further, cAbl régulâtes clearance of α-synuclein, a synaptic protein that has been strongly implicated in the pathogenesis of PD. A bi-directional relationship in vivo between α-synuclein and c-Abl has been described wherein an increase in α-synuclein expression facilitâtes its phosphorylation and subséquent activation of c-Abl. Conversely, an increase in the c-Abl expression and activation results in α-synuclein accumulation and aggregation, suggesting that inhibition of c-Abl might constitute a viable strategy for protecting dopaminergic neurons from accumulated α-synuclein toxicity in PD (Hébron et al., Hum. Mol. Genet., 2013; 22:3315-3328; Hébron et al., Autophagy, 2013; 9:1249-1250).
c-Abl inhibitors like nilotinib are known to cross the blood-brain barrier and protect dopaminergic neurons in a mouse model of PD induced with 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (herein referred to as MPTP) (Karuppagounder et al., Sci. Rep. 2014; 4:4874). Nilotinib has been shown to increase α-synuclein clearance via the autophagy pathway and protects against α-synuclein accumulation-induced loss of dopaminergic neurons in this mouse model of PD (Hébron et al., Hum. Mol. Genet., 2013; 22:3315-3328; Imam et al., J. Neurosci., 2011; 31:157-163). Further, US20150087653 discloses method of treating neurodegenerative diseases comprising of administering tyrosine kinase inhibitors such as nilotinib. However, nilotinib has several major drug associated adverse effects. USFDA has issued a boxed warning for Tasigna® capsules since its treatment is associated with potentially severe cardiac side effects (QT prolongation) and sudden deaths in patients. Dasatinib is known to cause pleural effusion and hemorrhage. Ponatinib is also associated with severe adverse effects which include thromboembolism and vascular occlusion. Imatinib is not a potent inhibitor of Abl kinase. Moreover, both imatinib and dasatinib being Pglycoprotein (p-gp) substrate, show poor brain concentration. . Thus, there is a need for a potent Abl kinase inhibitor which can cross the blood-brain barrier and does not cause cardiovascular side effects.
SUMMARY OF THE INVENTION
The invention provides method of treating or preventing Parkinson’s disease in a subject comprising administering a therapeutically effective amount of a compound of Formula I,
Formula I wherein, Rt is -NHC(O) C3.6 cycloalkyl and R2 is hydrogen;
or Rt and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C^e alkyl;
R3 and R4 are independently selected from group comprising hydrogen, halogen, C^ alkyl, OC^ alkyl, NO2, SC^s alkyl, 0^3 haloalkyl, 0Cv3 haloalkyl, and SC-|.3 haloalkyl; or its pharmaceutically acceptable sait thereof.
DESCRIPTION OF THE FIGURES
Fig.1. Photomicrographs from coronal sections showing tyrosine hydroxylase (TH)-positive neurons, showing prévention of neurodegeneration by the compound of Formula l.a.
Fig.2. Percentage area of TH-positive neurons on administration of the compound of Formula l.a.
Fig.3. Integrated density of TH-immunoreactivity on administration of the compound of Formula l.a.
Fig.4. Photomicrographs from coronal sections showing tyrosine hydroxylase (TH)-positive neurons, showing prévention of neurodegeneration by the compound of Formula l.b.
Fig.5. Percentage area of TH-positive neurons on administration of the compound of Formula l.b.
Fig.6. Integrated density of TH-immunoreactivity on administration of the compound of Formula l.b.
DETAILED DESCRIPTION OF THE INVENTION
In one aspect, the présent invention provides a method of treating or preventing Parkinson’s disease in a subject comprising administering a therapeutically effective amount of the compound of Formula I,
Formula I wherein, Rt is -NHC(O) C3.6 cycloalkyl and R2 is hydrogen;
or Rt and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and Ον6 alkyl;
R3 and R4 are independently selected from group comprising hydrogen, halogen, Ci.3 alkyl, OCi-3 alkyl, NO2, SC^ alkyl, C1.3 haloalkyl, 00^3 haloalkyl, and SCi.3 haloalkyl; or its pharmaceutically acceptable sait thereof.
In another aspect, the présent invention provides a method of treating or preventing Parkinson’s disease in a subject, comprising selecting a subject suffering from Parkinson’s disease or at risk of developing Parkinson’s disease and administering a therapeutically effective amount of a compound of Formula I.
The phrase “therapeutically effective amount of compound of Formula I” as used herein refers to amount of the compound of Formula I that elicit the therapeutic effect for which it is administered.
The term alkyP refers to a saturated hydrocarbon chain radical that includes solely carbon and hydrogen atoms in the backbone, either linear or branched and which is attached to the rest of the molécule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl and n-pentyl.
The numerical in phrases like “Cve alkyl”, refers that there are 1 to 6 carbon atoms in the alky chain.
The term “C3.6 cycloalkyf refers to a non-aromatic mono-cyclic ring System of 3 to 6 carbon atoms. Monocyclic rings include cylcopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term “haloalkyf refers to alkyl chain substituted with one or more halogen radical selected from chloride, bromide, iodide and fluoride.
In one embodiment, the présent invention provides method of treating or preventing Parkinson’s disease comprising administering a therapeutically effective amount of a compound of Formula I wherein FL in the compound of Formula I is -NHC(O) cyclopropyl and R2 is hydrogen.
In another embodiment, the présent invention provides a method of treating or preventing 5 Parkmson’s disease comprising administering a therapeutically effective amount of a compound of Formula I wherein, Rd and R2 in the compound of Formula I, along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and Ον6 alkyl. Preferably, the aromatic ring is substituted with hydrogen i.e. unsubstituted.
In another embodiment, the présent invention provides a method of treating or preventing Parkmson’s disease comprising administering a therapeutically effective amount of a compound of Formula I wherein, Rt and R2 in the compound of Formula I, along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the 15 ring is substituted with hydrogen i.e. unsubstituted; and R3 is chloro and R4 is methyl and are présent as a substituent at 2 and 6 position in the ring.
In another embodiment, the présent invention provides a method of treating or preventing Parkmson’s disease comprising administering a therapeutically effective amount of a 20 compound of Formula I wherein, R3 and R4 in the compound of Formula I are selected from halogen and alkyl. In a preferred embodiment, R3 and R4 are halogen and methyl and are présent as a substituent at 2 and 6 position in the ring.
The Chemical name of some of the preferred compounds of Formula I are provided below in 25 Table 1.
Table 1:
Compound No. | Chemical name |
La | A/-(2-Chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]benzo hydrazide |
l.b | Cyclopropanecarboxylic acid (5-{5-[N'-(2-chloro-6- methylbenzoyl)hydrazine carbonyl]-2-methyl-phenylethynyl}-pyridin-2- |
yl)amide | |
l.c | Cyclohexanecarboxylic acid (5-{5-[N'-(2-chloro-6- methylbenzoyl)hydrazine carbonyl]-2-methyl-phenylethynyl}-pyridin-2yl)amide |
l.d | Cyclobutanecarboxyhc acid (5-{5-[N'-(2-chloro-6-methylbenzoyl) hydrazine carbonyl]-2-methyl-phenylethynyl}-pyridin-2-yl)amide |
Le | A/-(2-Chloro-6-methylbenzoyl)-4-methyl-3-[2-(6-chloro-3quinolyl)ethynyl]-benzohydrazide |
l.f | /V-(2-Chloro-6-methylbenzoyl)-4-methyl-3-[2-(6-methyl-3-quinolyl) ethynyl]-benzohydrazide |
ig | A/-(2-Chloro-6-methylbenzoyl)-4-methyl-3-[2-(6-fluoro-3quinolyl)ethynyl]-benzohydrazide |
Suitable pharmaceutically acceptable salts of the compound of the invention may be salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, and the like or of organic acids such as, for example, acetic acid, benzenesulfonic acid, methanesulfonic 5 acid, benzoic acid, citric acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartartic acid, or amino acids, such as glutamic acid or aspartic acid, and the like. One or more hydrogen atoms of the compound of Formula I may be deuteriated i.e. substituted with a deuterium atom.
WIPO publication WO2012098416 (the ‘416 publication) discloses a markush group of compounds active as c-Abl kinase inhibitors and their usefulness for the treatment of cancers like chronic myelogenous leukemia (CML). Compounds of Formula I of the présent invention may be prepared by the processes described in WO2012098416 and WO2016185490 which are incorporated herein by reference.
The inventors hâve found that the compound of Formula I of présent invention, are potent Abl kinase inhibitors and advantageously cross the blood-brain barrier effectively resulting in a high ratio of brain to plasma concentration for the compound of Formula I and a high therapeutic index.
Particularly, the inventors hâve found that the compound of Formula I, at therapeutically effective dose, is devoid of cardiovascular side effects when tested for its in vitro effect on hERG channel and its in vivo effect on ECG parameters like QT interval, QTC interval, QTcf interval and heart rate in conscious beagle dogs and guinea pig. The compound of Formula I was found to be safe as they did not show any undue effect on ECG parameters and heart rate as described herein in examples.
The compound of Formula I can be administered orally in the form of a suitable dosage form. A suitable dosage form may include tablet, pellets, capsule, sachet, pellets in sachet, pellets in capsule, powder, granules and the like. The compound of Formula I may be formulated in oral dosage form which may include pharmaceutically acceptable excipients which are in common knowledge of a person skilled in the art. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses pharmaceutically acceptable carriers which can be used for préparation of a suitable dosage form.
The following examples serve to illustrate the invention without limiting the invention in its scope.
EXAMPLE 1
Abl Kinase inhibition
In a final reaction volume of 25 pL, Abl (human) (5-10 mU) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 50 μΜ EAIYAAPFAKKK, 10 mM Mg(OAc)2 and [γ-33Ρ-ΑΤΡ] [spécifie activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room température, the reaction is stopped by the addition of 5 pL of a 3 % phosphoric acid solution. 10 pL of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol priorto drying and scintillation counting.
Results for the représentative compounds of Formula I are provided in Table-2.
Table 2: Comparative potencies of tyrosine kinase inhibitors in c-Abl
IC50 (nM) | |||||
La | l.b | Nilotinib | Ponatinib | Dasatinib | Imatinib |
0.9 | 0.6 | 18 | 0.4 | 0.27 | 190 |
EXAMPLE 2
Brain/plasma pharmacokinetic studies
To détermine whetherthe compound of Formula La crosses the blood-brain barrier, C57BL6 5 mice were administered orally at 30 mg/kg of the compound of Formula La, 100 mg/kg of nilotinib or 30 mg/kg of dasatinib. At 1, 4 & 8 hour time points post treatment, mice were anesthetized with isoflurane and a 0.4 mL of blood was withdrawn from retro-orbital plexus into eppendorf tubes containing 8 pL sodium heparin as an anticoagulant (100 lU/ml) and transferred to ice containers. Blood samples were centrifuged immediately for 7 min at 8500 10 rpm, 4 °C. Plasma was separated in the pre-labeled eppendorf tubes and stored at -70 °C till further analysis. Immediately thereafter, the mice were sacrificed, whole brain was removed and rinsed with ice-cold phosphate buffered saline (PBS) to remove extraneous blood and blot-dried. Brain tissue samples were weighed and homogenized in 1:2 volume of PBS using a tissue homogenizer and stored in labeled vials at -70 °C until further analysis.
Concentrations of the compound of Formula La in brain and plasma were determined using the LC-MS technique.
Brain to plasma ratio was found to be significantly higher for the compound of Formula La as compared to that for nilotinib or dasatinib (see Table 3).
Table 3: Concentration of compounds in Brain and Plasma.
Compoun ds | Treatment * (mg/kg) | Time point s (hr) | Plasma conc. (ng of compound/m L of plasma) | Brain conc. (ng of compound/g of brain tissue) | Ratio of brain conc./plas ma conc. |
Compoun d of Formula La | 30 | 1 | 4798 ± 858 | 1901 ±959 | 0.40 |
4 | 3167 ±50 | 510 ±367 | 0.16 | ||
8 | 2715 + 379 | 435 ±157 | 0.16 | ||
Nilotinib | 100 | 1 | 31683 ± 7958 | 380 ± 70 | 0.01 |
4 | 38813 ±11635 | 487±126 | 0.01 |
8 | 16988 ±2133 | 180 ±46 | 0.01 | ||
Dasatinib | 30 | 1 | 553 ± 550 | 23.4 ± 0 | 0.04 |
4 | 222 ±122 | 25 ±5 | 0.11 | ||
8 | BQL | 24 ±4 | - | ||
bUL-beluw the Ιιιηιί ot quantification |
EXAMPLE 3
Efficacy in animal model of Parkinson’s disease for compound of Formula l.a
C57BL/6 mice (6-8 weeks old, 25-30 g body weight) were administered orally with vehicle, the compounds of Formula l.a (10 or 30 mg/kg, once a day) for 7 days. On day 7, these animais received four intraperitoneal injections of a neurotoxin, 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP-HCI; 17 mg/kg free base; Sigma) in saline at 2 hour intervals. Daily dosing with compound continued for 7 additional days after the last injection of MPTP. Briefly, the compound was administered 6 days prior to MPTP administration, on the day of MPTP administration and 7 days after MPTP administration. Ail animais were sacrificed 7 days after the MPTP administration and brain tissues were processed for immunohistochemistry évaluation. The standard avidin-biotin method (Benno et al., Brain Res., 1982, 246.225-236) was used for the immunohistochemical détection of tyrosine hydroxylase (TH). Initially, the brains were sectioned at the substantia nigra pars compacta (SNPc) level using a cryostat and mounted on glass slides. The slides with brain sections were rinsed 3x5 minutes in 0.1 M PBS. The sections were first incubated for 30 minutes at room température with normal blocking sérum in 0.1 M PBS with 0.3 % Triton X-100 and for additional 2 hours with a rabbit polyclonal antibody to mouse tyrosine hydroxylase (Invitrogen) diluted 1:1000 in 0.1 M PBS with normal blocking sérum. The slides with sections were further rinsed 3x5 minutes in 0.1 M PBS and incubated for 1 hour at room température with a biotinylated anti-rabbit antibody (Vectastain® ABC kit). The sections were rinsed 3x5 minutes in 0.1 M PBS and incubated for 1 hour at room température with A and B solutions (Vectastain® ABC kit) diluted 1:50 in 0.1 M PBS. After 1 hour the sections were rinsed 3x5 minutes in 0.1 M PBS and incubated in the 3,3’-diaminobenzidine (DAB)/H2O2 solution (Sigma) for approximately 5-8 minutes (the development process was checked under microscope for an optimal signal-to-noise ratio). The sections were first rinsed 2x5 minutes in 0.1 M PBS and then with 3x5 minutes in Milli-Q water. The slides were cover shpped in glycerol-gelatin solution and kept at room température overnight for drying after which images of the stained brain sections were captured using a caméra attached to a microscope and anaslyzed using NIH ImageJ® software (NIH, Bethesda, MD). Images were analyzed by converting to 8-bit resolution and optimal brightness/contrast. Background and 5 pseudo signais on individual images were removed and area covered by cell bodies and fibers was measured. Percentage area compared to total image area and integrated density was calculated. Results obtained were compared for any inter-group or intra-group variation and statistical significance using GraphPad Prism® 6.0. Oral administration of the compound of Formula La significantly prevented the neurodegeneration induced by MPTP as seen from photomicrographs from coronal sections showing TH-positive neurons (Fig. 1), the détermination of percentage area of TH-positive neurons (Fig. 2) and integrated density of TH-immunoreactivity (Fig. 3)
EXAMPLE 4
Efficacy in animal model of Parkinson’s disease for compound of Formula l.b
Efficacy of compound of Formula l.b for treating the Parkinson’s disease was tested by the same method as described for the compound of Formula La in Example 3 above.
The results obtained were compared for any inter-group or intra-group variation and 20 statistical significance using GraphPad Prism® 6.0. Oral administration of the compound of
Formula Lb significantly prevented the neurodegeneration induced by MPTP as seen from photomicrographs from coronal sections showing TH-positive neurons (Fig. 4), the détermination of percentage area of TH-positive neurons (Fig. 5) and integrated density of TH-immunoreactivity (Fig. 6)
EXAMPLE 5
Electrophysiological Procedures- Effect on hERG K* Channel
The compound of Formula La and Lb were tested for cardiovascular safety in an in vitro test to détermine inhibition of hERG K+ channel. The compounds of Formula La and Lb did not 30 show any significant inhibition of hERG current at the concentration tested.
The in vitro effect of the compounds of Formula La and Lb on ionic currents in voltageclamped human embryonic kidney cells (HEK293) that stably express the human ether-à-go11 go-related gene (hERG) was examined. Two concentrations of the compounds of Formula La and Lb (1 and 10 μΜ) were tested at near physiological température.
Cells were transferred to the recording chamber and superfused with vehicle control solution 5 (HEPES-buffered physiological saline solution+1 % dimethylsulfoxide + 1 % Bovine sérum albumin). Micropipette solution for whole cell patch clamp recordings was composed of : potassium aspartate, 130 mM; MgCI2, 5 mM; EGTA, 5 mM; ATP, 4 mM; HEPES, 10 mM; pH adjusted to 7.2 with 10N KOH. Micropipette solution was prepared in batches, aliquoted, stored frozen and a fresh aliquot thawed each day. The recording was performed at a 10 température of 33 to 35 °C using a combination of in4ine solution pre-heater, chamber heater and feedback température controller. Température was measured using a thermistor probe in the recording chamber. Micropipettes for patch clamp recording were made from glass capillary tubing using a P-97 micropipette puller (Sutter Instruments, Novato, CA). A commercial patch clamp amplifier was used for whole cell recordings. Before digitization, 15 current records were low-pass filtered at one-fifth of the sampling frequency.
Cells stably expressing hERG were held at -80 mV. Onset and steady State inhibition of hERG potassium current due to the test compounds (Formula La and Lb) were measured using a puise pattern with fixed amplitudes (conditioning prepulse +20 mV for 1 s; 20 repolanzing test ramp to -80 mV (-0.5 V/s) repeated at 5 s intervals). Each recording ended with a final application of a supra-maximal concentration of the reference substance (E-4031, 500 nM) to assess the contribution of endogenous currents. The remaining uninhibited current was subtracted off-line digitally from the data to détermine the potency of the test compounds for hERG inhibition.
The compound of Formula La inhibited hERG current by (Mean ± SEM) 2.1 ± 0.4 % at 1 μΜ (n = 3) and 9.7 ± 0.4 % at 10 μΜ (n = 3) compared to 1.0 ± 0.6 % (n = 3) in vehicle control (see Table 4). Concentrations of the compound of Formula La greater than 10 μΜ were not tested due to the solubility limit of the compound in the vehicle control. Under similar 30 conditions, the positive control (terfenadine, 60 nM) inhibited hERG potassium current by (Mean ± SD; n = 2) 82.8 ± 1.2 %, confirming a slight effect of the compound of Formula La at its very high concentration in hERG K+ channeL In comparison nilotinib shows nearly 90 % inhibition at 1 μΜ concentration (Table 5).
Table 4: Mean percent inhibition of hERG current at each concentration of the compound of Formula La and l.b.
Compound | Concentratio η (μΜ) | Mean | SD | SEM | N |
Compound l.a | 0 | 1.0 % | 1.0 % | 0.6 % | 3 |
1 | 2.1 % | 0.7 % | 0.4 % | 3 | |
10 | 9.7 % | 0.7 % | 0.4 % | 3 | |
Compound l.b | 0 | 1.6 % | 0.3 % | 0.2 % | 3 |
0.3 | 5.6 % | 1.3% | 0.8 % | 3 | |
1 | 12.9 %* | 4.1 % | 2.4 % | 3 | |
3 | 25.0 %* | 6.0 % | 3.4 % | 3 | |
value is statistically different from vehicle alone. |
# I
Table 5: percentage inhibition of hERG current by nilotinib#
Conc. (pM) | 0.03 | 0.1 | 0.3 | 1 |
% Inhibition | 14.9 ±2 | 43.9 ±0.7 | 70.4 ± 2.5 | 89.7 ±1.6 |
. 22-068 (Tasigna® Capsule) pg No.
review
EXAMPLE 6
Effect of compound of Formula l.a on QT, QTC intervals, and heart rate in conscious beagle dogs
The compound of Formula l.a was subjected to in vivo test to détermine its effect on the QT, QTcb & QTCf intervals, and heart rate in conscious beagle dogs.
Compound of Formula l.a was administered via pérorai (p.o.) route at three dose levels: 5, 15, and 30 mg/kg in conscious telemetered male and female beagle dogs. Emesis occurred in two animais (1 male and 1 female) treated with the 30 mg/kg dose group of the compound of Formula l.a at 14 min following dosing. Hence, the group treated with 30 mg/kg dose was not considered for the data analysis. No emesis was observed with 5 and 15 mg/kg doses.
Measurements of ECG parameters (QT interval, QTcb interval, QTcf interval) and heart rate were carried out and recorded over a period of 2 hour prior to drug administration (baseline), and continuously up to 24 hour post-administration. Each animal received both vehicle (placebo) and three different doses of the compound of Formula l.a on different days in a 5 Latin square design, with a washout period of a minimum of 96 hr. On a separate day, one additional oral dosing of compound of Formula l.a was performed to assess plasma concentrations of the compound of Formula l.a at different time points, to dérivé pharmacokinetic (PK) parameters.
Data of ECG parameters (QT interval, QTcb interval, QTcf interval,) and heart rate were statistically compared as follows: Data of the placebo group at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 24 hour time points were compared with baseline data of the same group. Data of different groups treated with the compound of Formula l.a were compared with the corresponding data of the placebo group.
Analysis of ECG based on pooled data of male and female dogs showed that as compared to baseline, placebo treatment had no statistically significant effect on any of the ECG parameters (QT interval, QTcb interval, QTcf interval) and heart rate. Compound of Formula La at 5 and 15 mg/kg doses had no effects on QT, QTcb, QTcf, durations compared with 20 placebo. In addition, other parameter such as heart rate remained unchanged.
The PK analysis showed a dose-dependent systemic exposure of the compound of Formula l.a to animais administered with different doses of the compound of Formula l.a. AUC0.inf was in the range of 1925 to 4824, 6776 to 12756, and 25927 to 46749 hrxng/mL with 5, 15, and 25 30 mg/kg doses of the compound of Formula l.a, respectively. Cmax was in the range of 1218 to 2033, 2723 to 5323, and 9825 to 9967 ng/mL with 5, 15, and 30 mg/kg doses of the compound of Formula l.a, respectively.
The results of this study showed that single oral administration of the compound of Formula La up to 15 mg/kg dose has no effect on cardiovascular functions in conscious beagle dogs.
There was no change in ECG morphology at any dose levels of the compound of Formula l.a. There were no gender différences in the treatment effect on ECG parameters and heart rate.
EXAMPLE 7
Effect of compound of Formula l.b on QT, QTc intervals, and heart rate in anesthetized guinea pig
The effect of compound of Formula l.b on QT, QTc intervals, and heart rate was studied in anesthetized guinea pig.
Male Dunkm-Hartley guinea pigs of body weight range 300-400 g were anaesthetized by intraperitoneal injection of urethane (1.5 g/kg). A tracheotomy was performed and animal was allowed to breath spontaneously throughout the experiment. The left jugular vein was catheterized using polyethylene cathéter filled with heparinized saline solution (100 IU/ mL) for drug administration. Electrodes were placed in lead II position and baseline ECG was recorded.
For different animais, according to body weight, doses of the compound of Formula l.b were weighed and prepared in 0.5 mL of DMSO and administered via a slow intravenous infusion administered over a period of 10 min. ECGs were recorded during and after completion of infusion up to 0.5 hr. QT and RR intervals were measured, using PowerLab 4SP® software. The data were analyzed at 1, 5, and 10 min during infusion and 5, 10, 15 and 30 min after infusion taking mean of 9 beats.
There was no change in QT intervals with administration of 1 mg/kg intravenous dose of the comP°und °f Formula | b
Claims (8)
1. Use of a compound of Formula R1 ^N.
R3 R4
Formula I wherein, FL is -NHC(O) C3.6 cycloalkyl and R2 is hydrogen;
or and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C^e alkyl;
R3 and R4 are independently selected from group comprising hydrogen, halogen, Cv3 alkyl, OC^ alkyl, NO2, SC^ alkyl, haloalkyl, OC^ haloalkyl, and SC^s haloalkyl, in the manufacture of a médicament for use in a method of treating or preventing Parkinson’s disease.
2. The use as claimed in claim 1, wherein R3 and R4 in the compound of Formula I are selected from halogen and alkyl.
3. The use as claimed in either of daims 1 and 2, wherein Rt in the compound of Formula I is -NHC(O) cyclopropyl and R2 is hydrogen.
4. The use as claimed in any one of the preceding daims, wherein Rt and R2 in the compound of Formula I, along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C^e alkyl.
5. A compound of Formula I
R3 R4
Formula I wherein, R-, is -NHC(O) C3.6 cycloalkyl and R2 is hydrogen;
or Rt and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and alkyl;
R3 and R4 are independently selected from group comprising hydrogen, halogen, alkyl, OC^ alkyl, NO2, SC^ alkyl, haloalkyl, OC^a haloalkyl, and SCi.3 haloalkyl, for use in a method of treating or preventing Parkinson’s disease.
6. The compound as claimed in claim 5, wherein R3 and R4 in the compound of Formula I are selected from halogen and alkyl.
7 The compound as claimed in either of daims 5 and 6, wherein Rt in the compound of Formula I is -NHC(O) cyclopropyl and R2 is hydrogen.
8. The compound as claimed in any one of daims 5 to 7, wherein Rt and R2 in the compound of Formula I, along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and alkyl.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201621019087 | 2016-06-02 | ||
IN201621019185 | 2016-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19279A true OA19279A (en) | 2020-06-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11813252B2 (en) | Treatment for Parkinson's disease | |
JP6509386B2 (en) | Compounds for treating mTOR pathway related diseases | |
NO332772B1 (en) | Use of receptor tyrosine kinase inhibitor for the preparation of a unit dose drug for the treatment of cancer | |
WO2020259528A1 (en) | Method for treating idiopathic pulmonary fibrosis | |
JP2009521470A (en) | Treatment of synuclein disorder | |
JP2004529916A (en) | Adenosine A2A receptor antagonist in combination with a neurotrophic active compound in the treatment of Parkinson's disease | |
US20200397777A1 (en) | Prevention and treatment of organ fibrosis | |
JP2020525446A (en) | Modulators of cystic fibrosis transmembrane conductance regulator for treating autosomal dominant polycystic kidney disease | |
JP2010531854A (en) | Pirenzepine and its derivatives as anti-amyloid agents | |
OA19279A (en) | Treatment for Parkinson's disease. | |
JP2010531854A5 (en) | ||
CZ289533B6 (en) | Use of dihydropyridine derivatives with annellated carbon or heterocyclic rings for the preparation of pharmaceutical preparations intended for protection of brain tissue | |
EA037697B1 (en) | Treatment for parkinson's disease | |
US20030166673A1 (en) | Medicines for the prevention and treatment of neurodegenerative diseases | |
US20100331363A1 (en) | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor | |
US20210308138A1 (en) | Tissue transglutaminase modulators for medicinal use | |
JP2022530890A (en) | How to treat a cough by using a diaminopyrimidine compound | |
WO2018203559A1 (en) | Pharmaceutical compositions for polyglutamine diseases | |
ITMI20110208A1 (en) | HETEROCYCLES WITH ANTI-HYPERTENSIVE ACTIVITY | |
JP2000505425A (en) | Methods of treating conditions associated with beta-amyloid peptide using TRH |